Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
QuintilesIMS
Queensland Health
Johnson and Johnson
McKesson
Cipla
Boehringer Ingelheim
Colorcon
Moodys

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021014

« Back to Dashboard

NDA 021014 describes TRILEPTAL, which is a drug marketed by Novartis and is included in two NDAs. It is available from four suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the TRILEPTAL profile page.

The generic ingredient in TRILEPTAL is oxcarbazepine. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.
Summary for 021014
Tradename:TRILEPTAL
Applicant:Novartis
Ingredient:oxcarbazepine
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021014
Suppliers and Packaging for NDA: 021014
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRILEPTAL oxcarbazepine TABLET;ORAL 021014 NDA Novartis Pharmaceuticals Corporation 0078-0337 0078-0337-05 100 TABLET, FILM COATED in 1 BOTTLE (0078-0337-05)
TRILEPTAL oxcarbazepine TABLET;ORAL 021014 NDA Novartis Pharmaceuticals Corporation 0078-0337 0078-0337-06 100 BLISTER PACK in 1 BOX, UNIT-DOSE (0078-0337-06) > 1 TABLET, FILM COATED in 1 BLISTER PACK (0078-0337-61)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength150MG
Approval Date:Jan 14, 2000TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Aug 12, 2018Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength300MG
Approval Date:Jan 14, 2000TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Aug 12, 2018Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength600MG
Approval Date:Jan 14, 2000TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Aug 12, 2018Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021014

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-001 Jan 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-003 Jan 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-002 Jan 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Teva
Fuji
Federal Trade Commission
Express Scripts
Chubb
Merck
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.